Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Repurposing of long-acting incretin-based therapies, including the GLP-1 receptor agonist semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple GLP-1/GIP/glucagon agonist retatrutide, may offer a promising strategy treating AUD
Our personalized semaglutide programs are tailored to each individuals needs, ensuring optimal outcomes
GIP receptor activation adds a second dimension to Retatrutides metabolic effects
The FDA still has to act on it, and formal rulemaking takes time - but we're ready to serve patients and providers when a regulatory pathway opens
These agents enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, slow gastric emptying, and promote satiety through central nervous system pathways
Discuss needle options with your healthcare provider if you have concerns
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
